<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986296</url>
  </required_header>
  <id_info>
    <org_study_id>OCD001</org_study_id>
    <nct_id>NCT01986296</nct_id>
  </id_info>
  <brief_title>ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Medication Refractory Obsessive Compulsive Disorder</brief_title>
  <official_title>A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound Treatment of Medication-Refractory OCD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSightec</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSightec</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this prospective, non-randomized, single-arm, single site, feasibility study is
      to develop and collect data to evaluate the safety and initial effectiveness of this
      treatment using this ExAblate transcranial System in the treatment of Medication-Refractory
      OCD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided
      focused ultrasound thermal ablation of a designated area in the brain of patients suffering
      from medication-refractory OCD, using the ExAblate transcranial system.

      The ExAblate system is a medical device that involves a focused ultrasound system and an MRI
      scanner. ExAblate delivers a pulse of focused ultrasound energy, or sonication, to the
      targeted tissue. For OCD Patients: one or more thermal lesion will be created on one of the
      following targets: Anterior cingulate cortex, Anterior Limb of internal Capsule, Ventral
      Striatum or Subgenual Cingulate Cortex.

      The treatment begins with a series of standard diagnostic MR images to identify the location
      and shape of tumor to be treated. The ExAblate computer uses the physician's designation of
      the target volume to plan the best way to cover the target volume with small spots called
      &quot;sonications&quot;. These treatment spots are cylinder shaped. Their size depends on sonication
      power and duration. During the treatment, a specific MR scan, which can be processed to
      identify changes in tissue temperature, provides a thermal map of the treatment volume to
      confirm the therapeutic effect. The thermal map is used to monitor the treatment in progress,
      and confirm that the ablation is proceeding according to plan, thus closing the therapy loop.

      The ExAblate transcranial operates a helmet-shaped transducer (currently utilizing
      1000-element phased array transducer) positioned above the subject head. The ExAblate
      transcranial system also includes means to immobilize the subject head, cool the interface
      water, and software for CT analysis and phase correction computation.

      After informed consent and screening, eligible subjects will proceed to the treatment. All
      subjects will be followed at Day 1, 7 days, 1 month, 6 months and 1, 2 and 3 years. At follow
      up visits, patients will be evaluated for general health, neurological changes (including
      MMSE exam),and efficacy measurements as well as for device/procedure related adverse events
      that may have occurred during the follow-up period. Six (6) month and 1, 2 and 3 year follow
      up visits will also include Full Battery Cognitive/Neurological Testing.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effectiveness of the ExAblate Transcranial MRgFUS treatment of medication-refractory OCD</measure>
    <time_frame>Participants will be followed from the date of treatment until study completion, up to 36 months</time_frame>
    <description>Effectiveness of the ExAblate Transcranial MR-guided Focused Ultrasound (MRgFUS) treatment of medication-refractory OCD will be determined using the Yale-Brown Obsessive-Compulsive Disorder Scale (Y-BOCS), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A) from examinations at baseline and through 6-Months post-ExAblate treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device or procedure related Adverse Events reported</measure>
    <time_frame>36 month</time_frame>
    <description>Safety of the ExAblate transcranial treatment will be determined by an evaluation of the incidence and severity of device and procedure related complications from the first / treatment day visit through the 6-Months post-treatment time point. All Adverse Events (AEs) will be reported and categorized by investigators as definitely, probably, possibly, or unrelated to the device, procedure, or post-surgical changes in neurological status. Alternative treatments resulting from post-surgical changes in neurological status will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Medication-refractory Obsessive Compulsive Disorder (OCD)</condition>
  <arm_group>
    <arm_group_label>ExAblate Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ExAblate Transcranial MRgFUS System</intervention_name>
    <description>Treatment with the ExAblate Transcranial MRgFUS System.</description>
    <arm_group_label>ExAblate Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women, between 18 and 65 years, inclusive

          2. Subjects who are able and willing to give consent and able to attend all study visits

          3. OCD refractory to adequate trials of medication and behavioral therapy by psychiatrist
             (more than 12 weeks at the maximum tolerated dose with more than two types of
             serotonin reuptake inhibitors).

          4. Designated Ablation Targets can be target by the ExAblate device. Designated Ablation
             Targets must be apparent on MRI such that targeting can be performed with direct
             visualization.

          5. Able to communicate sensations during the ExAblate MRgFUS treatment

          6. Definitive diagnosis of OCD, according to the criteria of the Diagnostic and
             Statistical Manual of Mental Disorder fourth edition (DSM-IV), with disease duration
             of more than 3 years, with diagnosed psychosocial dysfunction. (The diagnosis of OCD
             would be done by psychiatrist)

          7. A score on the Y-BOCS of more than 28.

          8. OCD medication regimen is stable for at least 30 days before enrolment

          9. Patients with diagnosed psychosocial dysfunction influenced by OCD

        Exclusion Criteria:

          1. Patients with unstable cardiac status including:

               1. Unstable angina pectoris on medication

               2. Patients with documented myocardial infarction within last 40 days to protocol
                  entry

               3. Congestive heart failure NYHA Class IV

          2. Patients exhibiting any behavior(s) consistent with ethanol or substance abuse as
             defined by the criteria outlined in the DSM-IV as manifested by one (or more) of the
             following occurring within a 12 month period:

               -  Recurrent substance use resulting in a failure to fulfill major role obligations
                  at work, school, or home (such as repeated absences or poor work performance
                  related to substance use; substance-related absences, suspensions, or expulsions
                  from school; or neglect of children or household).

               -  Recurrent substance use in situations in which it is physically hazardous (such
                  as driving an automobile or operating a machine when impaired by substance use)

               -  Recurrent substance-related legal problems (such as arrests for substance related
                  disorderly conduct)

               -  Continued substance use despite having persistent or recurrent social or
                  interpersonal problems caused or exacerbated by the effects of the substance (for
                  example, arguments with spouse about consequences of intoxication and physical
                  fights).

          3. Severe hypertension (diastolic BP &gt; 100 on medication)

          4. Patients with standard contraindications for MR imaging such as non-MRI compatible
             implanted metallic devices including cardiac pacemakers, size limitations, etc.

          5. Known intolerance or allergies to the MRI contrast agent (e.g. Gadolinium/Magnevist)
             including advanced kidney disease

          6. Patients receiving dialysis

          7. History of abnormal bleeding and/or coagulopathy

          8. Receiving anticoagulant (e.g. Warfarin) or antiplatelet (e.g. aspirin) therapy within
             one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage
             (e.g. Avastin) within one month of scheduled focused ultrasound procedure

          9. Active or suspected, acute or chronic uncontrolled infection or known life-threatening
             systemic disease

         10. History of intracranial hemorrhage

         11. Cerebrovascular disease (multiple CVA or CVA within 6 months)

         12. Evidence for calcifications that might interfere with treatment safety (per CT)

         13. Individuals who are not able or willing to tolerate the required prolonged stationary
             supine position during treatment (can be up to 4 hrs of total table time.)

         14. Symptoms and signs of increased intracranial pressure (e.g. headache, nausea,
             vomiting, lethargy, and papilledema)

         15. Patients unable to communicate with the investigator and staff

         16. Presence of any other neurodegenerative disease like Parkinson-plus syndromes
             suspected on neurological examination. These include:

               1. Multisystem atrophy

               2. Progressive supranuclear palsy

               3. Dementia with Lewy bodies

               4. Alzheimer's disease

         17. Subjects diagnosed with idiopathic Parkinson's disease.

         18. Presence of significant cognitive impairment as determined with a score â‰¤ 24 on the
             Mini Mental Status Examination (MMSE)

         19. History of immunocompromise, including patient who are HIV positive

         20. Patients with a history of seizures within the past year

         21. Patients with risk factors for intraoperative or postoperative bleeding:

               1. Platelet count less than 100,000 per cubic millimeter

               2. PT &gt; 14

               3. PTT &gt; 36

               4. INR &gt; 1.3

               5. Documented coagulopathy

               6. Patients receiving medications that are known to induce or contribute to
                  Hemorrhages

         22. Patients with any types of brain tumors, including metastases

         23. Any illness that in the investigator's opinion preclude participation in this study

         24. Pregnancy or lactation

         25. Patients who have had deep brain stimulation or a prior stereotactic ablation of
             Designated Ablation Target

         26. OCD medication regimen is not stable for at least 30 days before enrolment

         27. Legal incapacity or limited legal capacity

         28. Subjects with remarkable atrophy and poor healing capacity of the scalp (&gt; 30% of the
             skull area traversed by the sonication pathway)

         29. Are participating or have participated in another clinical trial in the last 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Woo Chang, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunjung Kweon</last_name>
      <phone>+ 82-10-2603-2912</phone>
      <email>KWEONEJ@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Hyun Ho Jung, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Won Seok Chang, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Se Joo Kim, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ji Hee Kim, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Woo Chang, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.insightec.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>August 7, 2016</last_update_submitted>
  <last_update_submitted_qc>August 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

